{"id":334557,"date":"2020-03-12T01:00:00","date_gmt":"2020-03-12T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/un-traitement-combine-avec-des-inhibiteurs-de-points-de-controle-permet-datteindre-le-but-recherche\/"},"modified":"2020-03-12T01:00:00","modified_gmt":"2020-03-12T00:00:00","slug":"un-traitement-combine-avec-des-inhibiteurs-de-points-de-controle-permet-datteindre-le-but-recherche","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/un-traitement-combine-avec-des-inhibiteurs-de-points-de-controle-permet-datteindre-le-but-recherche\/","title":{"rendered":"Un traitement combin\u00e9 avec des inhibiteurs de points de contr\u00f4le permet d&#8217;atteindre le but recherch\u00e9"},"content":{"rendered":"<p><strong>Les progr\u00e8s dans le traitement du cancer du poumon \u00e0 petites cellules ont \u00e9t\u00e9 rares ces derni\u00e8res ann\u00e9es. Les r\u00e9sultats de deux \u00e9tudes montrent maintenant un avantage de survie pour la combinaison de la chimioth\u00e9rapie et de l&#8217;immunoth\u00e9rapie.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>Pendant plus de 20 ans, il n&#8217;y a rien eu de positif \u00e0 signaler concernant le cancer du poumon \u00e0 petites cellules. Les r\u00e9sultats de deux \u00e9tudes combinant la chimioth\u00e9rapie et l&#8217;immunoth\u00e9rapie ont chang\u00e9 la donne.<\/p>\n<p>Dans cette \u00e9tude ouverte de phase III, 805 patients atteints de cancer du poumon \u00e0 petites cellules (ES-SCLC), na\u00effs de traitement, ont \u00e9t\u00e9 randomis\u00e9s 1:1. L&#8217;un des groupes a re\u00e7u quatre cycles de chimioth\u00e9rapie \u00e0 base d&#8217;\u00e9toposide\/platine plus 1500 mg de durvalumab toutes les 3 semaines, suivis de durvalumab toutes les 4 semaines. Le second groupe a re\u00e7u jusqu&#8217;\u00e0 6 cycles de chimioth\u00e9rapie \u00e0 base d&#8217;\u00e9toposide\/platine toutes les 3 semaines, ainsi qu&#8217;une irradiation prophylactique du cr\u00e2ne \u00e0 la discr\u00e9tion de l&#8217;investigateur. Plus de la moiti\u00e9 (56,8%) des patients du bras contr\u00f4le ont re\u00e7u 6 cycles de traitement. La m\u00e9diane de survie globale (OS) \u00e9tait de 10,3 mois dans le bras contr\u00f4le et a augment\u00e9 \u00e0 13,0 mois avec le traitement combin\u00e9. Cela correspond \u00e0 une r\u00e9duction de 27% du risque de d\u00e9c\u00e8s (HR:0,73 ; IC \u00e0 95%, 0,591-0,909 ; p=0,0047). En outre, les patients du groupe combin\u00e9 ont \u00e9t\u00e9 num\u00e9riquement moins nombreux \u00e0 d\u00e9velopper de nouvelles l\u00e9sions (41,4% contre 47,2%). L&#8217;expression de PD-L1 \u00e9tait faible et ne semblait pas \u00eatre un biomarqueur pr\u00e9dictif.<\/p>\n<p>&nbsp;<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-13012\" alt=\"\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2020\/03\/tab1_oh6_s29.png\" style=\"height:199px; width:600px\" width=\"1100\" height=\"364\"><\/p>\n<p>&nbsp;<\/p>\n<p>La deuxi\u00e8me \u00e9tude de phase III, men\u00e9e en double aveugle, randomis\u00e9e et contr\u00f4l\u00e9e par placebo, a \u00e9galement d\u00e9montr\u00e9 une am\u00e9lioration statistiquement et cliniquement significative de la SG et de la survie sans progression gr\u00e2ce \u00e0 l&#8217;association 1L-carboplatine + \u00e9toposide, \u00e0 laquelle a \u00e9t\u00e9 ajout\u00e9 un anti-PD-L1<strong> (tableau 1).<\/strong><\/p>\n<p><em>Source : European Society for Medical Oncology (ESMO) 2019<\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Litt\u00e9rature compl\u00e9mentaire :<\/p>\n<ul>\n<li>Paz-Ares L, et al. : Expression de PD-L1, sch\u00e9mas de progression et r\u00e9sultats rapport\u00e9s aux patients (PROs) avec durvalumab plus platine-\u00e9toposide dans ES-SCLC : r\u00e9sultats de CASPIAN<\/li>\n<li>Reck M, et al. : IMpower133 : Updated overall survival analysis of first-line atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><em>InFo ONKOLOGIE &amp; H\u00c4MATOLOGIE 2019 ; 7(6) : 29 (publi\u00e9 le 7.12.19, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Les progr\u00e8s dans le traitement du cancer du poumon \u00e0 petites cellules ont \u00e9t\u00e9 rares ces derni\u00e8res ann\u00e9es. Les r\u00e9sultats de deux \u00e9tudes montrent maintenant un avantage de survie pour&hellip;<\/p>\n","protected":false},"author":7,"featured_media":93647,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cancer du poumon \u00e0 petites cellules ","footnotes":""},"category":[11527,11389,11477,11535,11549],"tags":[18865,13586,15965],"powerkit_post_featured":[],"class_list":["post-334557","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-oncologie","category-pneumologie-fr","category-rapports-de-congres","category-rx-fr","tag-cancer-du-poumon-fr","tag-immunotherapie-fr","tag-inhibiteur-de-point-de-controle","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-11 20:58:58","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":334561,"slug":"la-terapia-combinata-con-gli-inibitori-del-checkpoint-e-efficace","post_title":"La terapia combinata con gli inibitori del checkpoint \u00e8 efficace","href":"https:\/\/medizinonline.com\/it\/la-terapia-combinata-con-gli-inibitori-del-checkpoint-e-efficace\/"},"pt_PT":{"locale":"pt_PT","id":334513,"slug":"terapia-combinada-com-inibidores-de-pontos-de-controlo-eficazes","post_title":"Terapia combinada com inibidores de pontos de controlo eficazes","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-combinada-com-inibidores-de-pontos-de-controlo-eficazes\/"},"es_ES":{"locale":"es_ES","id":334524,"slug":"la-terapia-combinada-con-inhibidores-de-puntos-de-control-es-eficaz","post_title":"La terapia combinada con inhibidores de puntos de control es eficaz","href":"https:\/\/medizinonline.com\/es\/la-terapia-combinada-con-inhibidores-de-puntos-de-control-es-eficaz\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/334557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=334557"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/334557\/revisions"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=334557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=334557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=334557"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=334557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}